These regulatory effects are linked to the inhibition of the Akt and EGFR signaling pathways, as well as the modulation of the aryl hydrocarbon receptor signaling axis, which is implicated in glioblastoma malignancy (Figure 7). This evidence concerns the gene AKT1 and glioblastoma.